Device Trial Radar · NCT01136369
Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
496
Actual
Start
Feb 2007
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Sysmex America, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 3, 2010
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H\&E) and IHC staining.
Conditions
- Breast Neoplasms
- Breast Diseases
Interventions
OSNA Breast Cancer SystemDevice
For in vitro diagnostic use only. The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm). Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section staining.Time frame: 2 years
- The time required to perform the trial method will be measured and evaluated for intra-operative use.Time frame: 2 Years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
John Wayne Cancer Institute
Santa Monica, California
WellStar Health Systems
Marietta, Georgia
Washington University Medical School
St Louis, Missouri
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.